nach oben

Journal of Neuro-Oncology

Erschienen in:

18.01.2018 | Topic Review

Tumor treating fields: a new approach to glioblastoma therapy

verfasst von: Jonathan Rick, Ankush Chandra, Manish K. Aghi

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Glioblastoma is an aggressive brain malignancy with poor outcomes. Current standard of care involves surgery, radiotherapy and chemotherapy. Even with optimal treatment, 5-year survival rates are low. Many patients are unable to tolerate the considerable side effects that therapy involves and suffer from low quality of life. Anti-mitotic tumor treating fields have shown potential in treating glioblastoma with data suggesting that they prolong disease-free survival and overall survival. Novocure has marketed a device that generates these fields via externally placed electrodes. Incorporation of electric field therapy into GBM treatment has been somewhat slow, due to concerns about cost, practicality of its usage from a patient perspective, and hesitation of the medical and scientific community to embrace its unconventional mechanism. However, clinical trials have demonstrated this therapy has relatively minor side effects and high patient compliance. In this review, we explore the current state of this technology and discuss the benefits and limitations of tumor treating fields.

Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR, Barnholtz-Sloan JS (2014) The epidemiology of glioma in adults: a state of the science review. Neuro Oncology 16:896–913. https://doi.org/10.1093/neuonc/nou087 CrossRefPubMedPubMedCentral

Sarkar A, Chiocca EA, Glioblastoma, Astrocytoma M (2012) Glioblastoma and malignant astrocytoma. Brain Tumors. https://doi.org/10.1016/B978-0-443-06967-3.00021-1

Zhu P, Du XL, Lu G, Zhu J-J (2017) Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: a population-based study. Oncotarget 8:44015–44031. https://doi.org/10.18632/oncotarget.17054 PubMedPubMedCentral

Woernle CM, Péus D, Hofer S, Rushing EJ, Held U, Bozinov O, Krayenbühl N, Weller M, Regli L (2015) Efficacy of surgery and further treatment of progressive glioblastoma. World Neurosurg 84:301–307. https://doi.org/10.1016/j.wneu.2015.03.018 CrossRefPubMed

Johnson DR, O’Neill BP (2012) Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 107:359–364. https://doi.org/10.1007/s11060-011-0749-4 CrossRefPubMed

Walid MS (2008) Prognostic factors for long-term survival after glioblastoma. Perm J 12:45–48PubMedPubMedCentral

Hottinger AF, Pacheco P, Stupp R (2016) Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro Oncology 18:1338–1349. https://doi.org/10.1093/neuonc/now182 CrossRefPubMedPubMedCentral

Aoki T, Hashimoto N, Matsutani M (2007) Management of glioblastoma. Expert Opin Pharmacother 8:3133–3146. https://doi.org/10.1517/14656566.8.18.3133 CrossRefPubMed

Hottinger AF, Stupp R, Homicsko K (2014) Standards of care and novel approaches in the management of glioblastoma multiforme. Chin J Cancer 33:32–39. https://doi.org/10.5732/cjc.013.10207 CrossRefPubMedPubMedCentral

10.

Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA, Black PM (2010) Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 28:3838–3843. https://doi.org/10.1200/JCO.2010.30.0582 CrossRefPubMedPubMedCentral

11.

Brown T, Brennan M, Li M, Church E, Brandmeir N, Rakszawski K, Patel A, Rizk E, Suki D, Sawaya R, Glantz M (2016) Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol 2:1460–1469. https://doi.org/10.1001/jamaoncol.2016.1373 CrossRefPubMed

12.

Vogelbaum MA (2012) Does extent of resection of a glioblastoma matter? Clin Neurosurg 59:79–81. https://doi.org/10.1227/NEU.0b013e31826b2e75 CrossRefPubMed

13.

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff R-O (2017) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. https://doi.org/10.1016/S1470-2045(09)70025-7 CrossRef

14.

Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY, Menei P, Loiseau H, Bernier V, Honnorat J, Barrie M, Mokhtari K, Mazeron JJ, Bissery A, Delattre JY, Association of French-Speaking Neuro-Oncologists (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535. https://doi.org/10.1056/NEJMoa065901 CrossRefPubMed

15.

Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037. https://doi.org/10.1056/NEJMoa1611977 CrossRefPubMed

16.

Taillibert S, Le Rhun E, Chamberlain MC (2015) Tumor treating fields. Curr Opin Neurol 28:659–664. https://doi.org/10.1097/WCO.0000000000000250 CrossRefPubMed

17.

Lok E, San P, Hua V, Phung M, Wong ET (2017) Analysis of physical characteristics of tumor treating fields for human glioblastoma. Cancer Med 6:1286–1300. https://doi.org/10.1002/cam4.1095 CrossRefPubMedPubMedCentral

18.

Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD, Tumor treating fields: a fourth modality in cancer treatment. Clin Cancer Res (2017). https://doi.org/10.1158/1078-0432.CCR-17-1117

19.

Weaver JC, Chizmadzhev YA (1996) Theory of electroporation: a review. Bioelectrochem Bioenergy 41:135–160. https://doi.org/10.1016/S0302-4598(96)05062-3 CrossRef

20.

Holzapfel C, Vienken J, Zimmermann U (1982) Rotation of cells in an alternating electric field theory and experimental proof. J Membr Biol 67:13–26. https://doi.org/10.1007/BF01868644 CrossRefPubMed

21.

Sugar IP, Neumann E (1984) Stochastic model for electric field-induced membrane pores electroporation. Biophys Chem 19:211–225. https://doi.org/10.1016/0301-4622(84)87003-9 CrossRefPubMed

22.

Giladi M, Schneiderman RS, Porat Y, Munster M, Itzhaki A, Mordechovich D, Cahal S, Kirson ED, Weinberg U, Palti Y (2014) Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. Pancreatology 14:54–63. https://doi.org/10.1016/j.pan.2013.11.009 CrossRefPubMed

23.

Berjano EJ (2006) Theoretical modeling for radiofrequency ablation: state-of-the-art and challenges for the future. Biomed Eng Online 5:24. https://doi.org/10.1186/1475-925X-5-24 CrossRefPubMedPubMedCentral

24.

Atroshi I, Gummesson C, Johnsson R, Ornstein E (2003) Diagnostic properties of nerve conduction tests in population-based carpal tunnel syndrome. BMC Musculoskelet Disord 4:9. https://doi.org/10.1186/1471-2474-4-9 CrossRefPubMedPubMedCentral

25.

Alanko T, Puranen L, Hietanen M (2011) Assessment of exposure to intermediate frequency electric fields and contact currents from a plasma ball. Bioelectromagnetics 32:644–651. https://doi.org/10.1002/bem.20675 CrossRefPubMed

26.

Kirson ED (2004) Disruption of cancer cell replication by alternating electric fields. Cancer Res 64:3288–3295. https://doi.org/10.1158/0008-5472.CAN-04-0083 CrossRefPubMed

27.

Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, Cahal S, Shteingauz A, Chaudhry A, Kirson ED, Weinberg U, Palti Y (2015) Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep 5:18046. https://doi.org/10.1038/srep18046 CrossRefPubMedPubMedCentral

28.

Giladi M, Weinberg U, Schneiderman RS, Porat Y, Munster M, Voloshin T, Blatt R, Cahal S, Itzhaki A, Onn A, Kirson ED, Palti Y (2014) Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo. Semin Oncol 41:S35–S41. https://doi.org/10.1053/j.seminoncol.2014.09.006 CrossRefPubMed

29.

Kirson ED, Dbalý V, Tovaryš F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y (2007) Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA 104:10152–10157. https://doi.org/10.1073/pnas.0702916104 CrossRefPubMedPubMedCentral

30.

Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, Wasserman Y, Ryffel B, Goldsher D, Palti Y (2009) Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis 26:633–640. https://doi.org/10.1007/s10585-009-9262-y CrossRefPubMedPubMedCentral

31.

Kirson ED, Schneiderman RS, Dbalý V, Tovarys F, Vymazal J, Itzhaki A, Mordechovich D, Gurvich Z, Shmueli E, Goldsher D, Wasserman Y, Palti Y (2009) Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys 9:1. https://doi.org/10.1186/1756-6649-9-1 CrossRefPubMedPubMedCentral

32.

Schneiderman RS, Shmueli E, Kirson ED, Palti Y (2010) TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters. BMC Cancer 10:229. https://doi.org/10.1186/1471-2407-10-229 CrossRefPubMedPubMedCentral

33.

Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH (2012) NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48:2192–2202. https://doi.org/10.1016/j.ejca.2012.04.011 CrossRefPubMed

34.

Lacouture ME, Elizabeth Davis M, Elzinga G, Butowski N, Tran D, Villano JL, Dimeglio L, Davies AM, Wong ET (2014) Characterization and management of dermatologic adverse events with the NovoTTF-100A system, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. Semin Oncol 41:S1–S14. https://doi.org/10.1053/j.seminoncol.2014.03.011 CrossRefPubMed

35.

Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu J-J, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma. Jama 314:2535. https://doi.org/10.1001/jama.2015.16669 CrossRefPubMed

36.

Zhu J-J, Demireva P, Kanner AA, Pannullo S, Mehdorn M, Avgeropoulos N, Salmaggi A, Silvani A, Goldlust S, David C, Benouaich-Amiel A (2017) Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. J Neurooncol. https://doi.org/10.1007/s11060-017-2601-y PubMedCentral

37.

Stupp R, Ram Z (2017) OS07.9 Standard of care temozolomide chemotherapy ± tumor treating fields (TTFields) in newly diagnosed glioblastoma. Final results of the phase III EF-14 clinical trial. Neuro Oncol 19:iii15. https://doi.org/10.1093/neuonc/nox036.050 CrossRef

38.

Stupp R, Hegi ME, Idbaih A, Steinberg DM, Lhermitte B, Read W, Toms SA, Barnett GH, Nicholas G, Kim C-Y, Fink K, Salmaggi A, Lieberman FS, Zhu J-J, Taylor L, Stragliotto G, Hottinger AF, Kirson ED, Weinberg U, Palti Y, Ram Z (2017) Abstract CT007: tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): final results of a randomized, multi-center, phase III trial. Cancer Res 77:CT007 LP-CT007. http://cancerres.aacrjournals.org/content/77/13_Supplement/CT007.abstract

39.

Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu J-J, Stragliotto G, Tran DD, Brem S, Hottinger AF, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim C-Y, Paek S-H, Nicholas G, Burna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306–2316. https://doi.org/10.1001/jama.2017.18718 CrossRefPubMed

40.

Kelly C, Majewska P, Ioannidis S, Raza MH, Williams M (2017) Estimating progression-free survival in patients with glioblastoma using routinely collected data. J Neurooncol 135:621–627. https://doi.org/10.1007/s11060-017-2619-1 CrossRefPubMedPubMedCentral

41.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330 CrossRefPubMed

42.

Mrugala MM, Engelhard HH, Dinh Tran D, Kew Y, Cavaliere R, Villano JL, Annenelie Bota D, Rudnick J, Love Sumrall A, Zhu J-J, Butowski N (2017) Clinical practice experience with NovoTTF-100A system for glioblastoma: the patient registry dataset (PRiDe). Semin Oncol 41:S4–S13. https://doi.org/10.1053/j.seminoncol.2014.09.010 CrossRef

43.

Gilbert MR, Dignam JJ, Armstrong TSTS., Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh SL, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJJ, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. https://doi.org/10.1056/NEJMoa1308573 CrossRefPubMedPubMedCentral

44.

Narita Y (2015) Bevacizumab for glioblastoma. Ther Clin Risk Manag 11:1759–1765. https://doi.org/10.2147/TCRM.S58289 CrossRefPubMedPubMedCentral

45.

Ansstas G, Tran DD (2016) Treatment with tumor-treating fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma: a case series. Case Rep Neurol 8:1–9. https://doi.org/10.1159/000442196 CrossRefPubMedPubMedCentral

46.

Jackson C, Ruzevick J, Brem H, Lim M, Manuscript A (2013) Vaccine strategies for glioblastoma: progress and future directions. Immunotherapy 5:155–167. https://doi.org/10.2217/imt.12.155 CrossRefPubMedPubMedCentral

47.

Novocure, Optune, Instruction for Use, 1st ed., Novocure, 2016. doi:QSD-QR-703

48.

Lukas RV, Ratermann KL, Wong ET, Villano JL (2017) Skin toxicities associated with tumor treating fields: case based review. J Neurooncol. https://doi.org/10.1007/s11060-017-2612-8

49.

Zhang I, Knisely JPS (2016) Tumor treating fields—effective, but at what cost? Transl Cancer Res 5:S1349–S1353. https://doi.org/10.21037/tcr.2016.12.45 CrossRef

50.

Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X (2016) The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 18:1129–1136. https://doi.org/10.1093/neuonc/now102 CrossRefPubMedPubMedCentral

51.

Korshoej AR, Hansen FL, Thielscher A, Von Oettingen GB, Christian J, Hedemann S (2017) Impact of tumor position, conductivity distribution and tissue homogeneity on the distribution of tumor treating fields in a human brain: a computer modeling study. PLoS ONE 12:e0179214. https://doi.org/10.1371/journal.pone.0179214 CrossRefPubMedPubMedCentral

52.

Chang E, Pohling C, Beygui N, Patel CB, Rosenberg J, Ha DH, Gambhir SS (2017) Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields. J Neurooncol. https://doi.org/10.1007/s11060-017-2534-5

53.

Wong ET, Lok E, Swanson KD, An evidence-based review of alternating electric fields therapy for malignant gliomas. Curr Treat Options Oncol (2015). https://doi.org/10.1007/s11864-015-0353-5 PubMedCentral

54.

Karanam NK, Srinivasan K, Ding L, Sishc B, Saha D, Story MD (2017) Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines. Cell Death Dis 8:e2711. https://doi.org/10.1038/cddis.2017.136 CrossRefPubMedPubMedCentral

55.

Holtzman T, IMST-26 (2016) Tumor treating fields exposure of tumor cells induce activation phenotype in immune cells. Neuro Oncology 18:vi92. https://doi.org/10.1093/neuonc/now212.382 CrossRef

Titel: Tumor treating fields: a new approach to glioblastoma therapy
verfasst von: Jonathan Rick
Ankush Chandra
Manish K. Aghi
Publikationsdatum: 18.01.2018
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2018
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2768-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype

Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?

Brentuximab vedotin-induced peripheral neuropathy: looking at microtubules

Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival

Unprecedented response to combination BRAF and MEK inhibitors in adult anaplastic ganglioglioma